We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 11-20 of 683

Humira patent invalid for obviousness type double patenting

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

In AbbVie Inc. v. Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed the district court's finding that a second patent covering

Will the USPTO respond to public feedback of its eligibility guidance?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 25 2014

Periodically, the USPTO holds open meetings with the public to discuss its thinking on current topics relating to the patent procurement process

Are permanent injunctions in patent cases back in style?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 21 2014

Two recent district court decisions out of the District of Delaware have again placed the spotlight on permanent injunctions in patent cases. Prior

Airing the USPTO’s naturally occurring dirty laundry -- the subject matter eligibility stain

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 21 2014

It has been five months since the USPTO issued its Guidance For Determining Subject Matter Eligibility of Claims Reciting Or Involving Laws of Nature

Yamanaka iPSC patent challenged

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 20 2014

Dr. Shinya Yamanaka of Kyoto University shared the 2012 Nobel Prize in Physiology or Medicine with Dr. John B. Gurdon for their respective

Federal Circuit upholds inequitable conduct defense against Apotex patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 18 2014

In Apotex Inc. v. UCB, Inc., the Federal Circuit upheld the district court's finding that Apotex's patent is unenforceable due to inequitable conduct

NPEs continue to play large role in patent litigation

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 17 2014

The annual patent litigation study recently released by PricewaterhouseCoopers LLP (PwC) sets forth some interesting trends in patent litigation

First post grant review petition shows that amending claims is not child's play

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 11 2014

The first Post Grant Review petition visible to the public was filed August 5, 2014, against U.S. Patent 8,684,420. The patent was granted from an

Federal Circuit finds that FDA citizen petition could give rise to antitrust liability

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 7 2014

In Tyco Healthcare Group LP v. Mutual Pharmaceutical Co., Inc., the Federal Circuit remanded-in-part for the district court to determine whether

Evolving healthcare trends & patents: charting a safe course for personalized medicine

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 5 2014

Rapid changes resulting from personalized medicine, including the ability to use individual patient biomarker data to generate a tailored treatment